Genmab A/S

Genmab A/S Rule of 40

The Rule of 40 of Genmab A/S (GMAB.CO) as of Oct 10, 2026 is -48.47 %. In the previous year, Rule of 40 was 63.20 % — a change of -176.69% (lower).

Rule of 40

-48.47 %

YoY

-176.69%

Last updated:

Rule of 40 of Genmab A/S is 2025 -48.47 % . Rule of 40 of Genmab A/S was 2024 63.20 % . It decreases by -176.69% lower compared to the previous year.

The Genmab A/S Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
73.52 USD
Jan 1, 2019
126.54 USD
Jan 1, 2020
150.86 USD
Jan 1, 2021
18.70 USD
Jan 1, 2022
114.48 USD
Jan 1, 2023
45.87 USD
Jan 1, 2024
63.20 USD
Jan 1, 2025
-48.47 USD
The Genmab A/S Rule of 40 history
YEARRule of 40YoY
-48.47 %-176.69%
63.20 %+37.77%
45.87 %-59.93%
114.48 %+512.05%
18.70 %-87.60%
150.86 %+19.22%
126.54 %+72.13%
73.52 %-15.57%
87.07 %-26.37%
118.26 %+21.04%
97.70 %—
Access this data via the Eulerpool API
Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Rule of 40 of Genmab A/S is -48.47 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API
Get Free API Key

Quality — Genmab A/S

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Genmab A/S